Biotech investors are having some not-so-happy holidays.
In the last few months, several major funds have reportedly seen double-digit drops in their biotech portfolios’ value — leading some to wonder if the sector’s remarkable run is really, finally over this time.
About the Author Reprints
Create a display name to comment
This name will appear with your comment
